What You Should Know: Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their innovative partnership enabling more eligible MassMutual policyowners to gain knowledge about their health in order to make informed, proactive decisions that may help them lead longer, healthier lives.The program offers a genetic risk assessment service to
Read More
genomics
Cone Health, Helix Launches 5-Year Population Genomics Testing Initiative
What You Should Know: - Cone Health, a non-profit healthcare network in North Carolina, and Helix, a population genomics company, have partnered to launch a five-year research study that will enroll and track 100,000 healthy people. - The study will use Helix's population genomics platform to provide medical insights for Cone Health patients and help identify people at risk for certain diseases and conditions. Study Enrollment & Benefits Enrollment in the program is optional and
Read More
UC Berkeley Bio Track Helps Faculty Launch Biotech Startups
What You Should Know: Berkeley SkyDeck, the global hub for entrepreneurship and a leading accelerator, today announced that it has welcomed the first three companies for its new SkyDeck LSEC Bio Track: AsparaGlue, Editpep, and MZR Neurotech.The inaugural track, created in partnership with the UC Berkeley Life Sciences Entrepreneurship Center (LSEC) through LSEC’s new Venture Grant Program, will assist the UC Berkeley faculty-led teams to launch their own biotech and life sciences
Read More
Quest Diagnostics Acquires Haystack Oncology for $300M in Cash
What You Should Know: Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care
What You Should Know: - A recent study published in JAMA found that conventional genomic tests commonly used for breast cancer tumors can be less accurate for Black women. This news comes at a time when Black women with breast cancer are experiencing mortality rates that are 41% higher than white women. - Dr. Nathalie Johnson, MD FACS and President of The American Society of Breast Cancer Surgeons is among numerous doctors who advocate for Agendia and its tests which look beyond race,
Read More
NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D
What You Should Know: - NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. - Part of NVIDIA AI Foundations, the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery. It
Read More
The Market Demand for Data-Driven Tech Solutions in Healthcare
The market demand for data-driven technology solutions in healthcare is on the rise. Today, one-third of the world's data is generated by the healthcare industry. This data is often complex and is coming from multiple different sources such as personal health information, claims data, clinical trial data, patient surveys, disease registries, population health statistics, wellness apps, and wearable devices. And so, the need for data management technologies continues to grow. In the Future Health
Read More
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know: - C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research. - Under this agreement, RG will work with C2i Genomics to commercialize
Read More
What Impact Could AI Have On Genetic Testing?
The sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the Human Genome Project. With DNA sequencing becoming increasingly cost-effective, the market for genetic testing is growing at an accelerating rate – the market for Next Generation Sequencing (NGS) services has an estimated annual growth of 18.3% from 2022 to 2030. AI presents a range of possibilities for this rapidly growing field, and in this article,
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know: - Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone. - This multi-omics approach is being used by Actuate Therapeutics in support
Read More